Cargando…

Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease

INTRODUCTION: The risk of death significantly increased from stage 3 chronic kidney disease (CKD) onward. We aimed to construct a novel nomogram to predict the overall survival (OS) of patients afflicted with CKD from stage 3–5. METHODS: A total of 882 patients with stage 3–5 CKD were enrolled from...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Zhou, Guowei, Zheng, Yawei, Zhou, Enchao, He, Weiming, Sun, Wei, Zhang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856074/
https://www.ncbi.nlm.nih.gov/pubmed/35166166
http://dx.doi.org/10.1080/0886022X.2022.2032744
_version_ 1784653765588025344
author Li, Ning
Zhou, Guowei
Zheng, Yawei
Zhou, Enchao
He, Weiming
Sun, Wei
Zhang, Lu
author_facet Li, Ning
Zhou, Guowei
Zheng, Yawei
Zhou, Enchao
He, Weiming
Sun, Wei
Zhang, Lu
author_sort Li, Ning
collection PubMed
description INTRODUCTION: The risk of death significantly increased from stage 3 chronic kidney disease (CKD) onward. We aimed to construct a novel nomogram to predict the overall survival (OS) of patients afflicted with CKD from stage 3–5. METHODS: A total of 882 patients with stage 3–5 CKD were enrolled from the NHANES 2001–2004 survey. Data sets from the 2003–2004 survey population were used to develop a nomogram that would predict the risk of OS. The 2001–2002 survey population was used to validate the nomogram. Least absolute shrinkage and selection operator (Lasso) regression was conducted to screen the significant predictors relative to all-cause death. The multivariate Cox regression based on the screened factors was applied to effectively construct the nomogram. The performance of the nomogram was evaluated according to the C-index, the area under the receiver operating characteristic curve (AUC), and the calibration curve with 1000 bootstraps resample. Kaplan–Meier’s curves were used for testing the discrimination of the prediction model. RESULTS: Five variables (age, urinary albumin-to-creatinine ratio (UACR), potassium, cystatin C (Cys C), and homocysteine) were screened by the Lasso regression. The nomogram was constructed using these factors, as well as the CKD stage. The included factors (age, CKD stage, UACR, potassium, Cys C, and homocysteine) were all significantly related to the death of CKD patients, according to the multivariate Cox regression analysis. The internal validation showed that this nomogram demonstrates good discrimination and calibration (adjusted C-index: 0.70; AUC of 3-, 5-, and 10-year OS were 0.75, 0.78, and 0.77, respectively). External validation also demonstrated exceedingly similar results (C-index: 0.72, 95% CI: 0.69–0.76; AUC of 3-, 5-, and 10-year OS were 0.76, 0.79, and 0.80, respectively). CONCLUSIONS: This study effectively constructed a novel nomogram that incorporates CKD stage, age, UACR, potassium, Cys C, and homocysteine, which can be conveniently used to facilitate the individualized prediction of survival probability in patients with stage 3–5 CKD. It displays valuable potential for clinical application.
format Online
Article
Text
id pubmed-8856074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88560742022-02-19 Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease Li, Ning Zhou, Guowei Zheng, Yawei Zhou, Enchao He, Weiming Sun, Wei Zhang, Lu Ren Fail Clinical Study INTRODUCTION: The risk of death significantly increased from stage 3 chronic kidney disease (CKD) onward. We aimed to construct a novel nomogram to predict the overall survival (OS) of patients afflicted with CKD from stage 3–5. METHODS: A total of 882 patients with stage 3–5 CKD were enrolled from the NHANES 2001–2004 survey. Data sets from the 2003–2004 survey population were used to develop a nomogram that would predict the risk of OS. The 2001–2002 survey population was used to validate the nomogram. Least absolute shrinkage and selection operator (Lasso) regression was conducted to screen the significant predictors relative to all-cause death. The multivariate Cox regression based on the screened factors was applied to effectively construct the nomogram. The performance of the nomogram was evaluated according to the C-index, the area under the receiver operating characteristic curve (AUC), and the calibration curve with 1000 bootstraps resample. Kaplan–Meier’s curves were used for testing the discrimination of the prediction model. RESULTS: Five variables (age, urinary albumin-to-creatinine ratio (UACR), potassium, cystatin C (Cys C), and homocysteine) were screened by the Lasso regression. The nomogram was constructed using these factors, as well as the CKD stage. The included factors (age, CKD stage, UACR, potassium, Cys C, and homocysteine) were all significantly related to the death of CKD patients, according to the multivariate Cox regression analysis. The internal validation showed that this nomogram demonstrates good discrimination and calibration (adjusted C-index: 0.70; AUC of 3-, 5-, and 10-year OS were 0.75, 0.78, and 0.77, respectively). External validation also demonstrated exceedingly similar results (C-index: 0.72, 95% CI: 0.69–0.76; AUC of 3-, 5-, and 10-year OS were 0.76, 0.79, and 0.80, respectively). CONCLUSIONS: This study effectively constructed a novel nomogram that incorporates CKD stage, age, UACR, potassium, Cys C, and homocysteine, which can be conveniently used to facilitate the individualized prediction of survival probability in patients with stage 3–5 CKD. It displays valuable potential for clinical application. Taylor & Francis 2022-02-15 /pmc/articles/PMC8856074/ /pubmed/35166166 http://dx.doi.org/10.1080/0886022X.2022.2032744 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Li, Ning
Zhou, Guowei
Zheng, Yawei
Zhou, Enchao
He, Weiming
Sun, Wei
Zhang, Lu
Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title_full Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title_fullStr Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title_full_unstemmed Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title_short Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
title_sort development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856074/
https://www.ncbi.nlm.nih.gov/pubmed/35166166
http://dx.doi.org/10.1080/0886022X.2022.2032744
work_keys_str_mv AT lining developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT zhouguowei developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT zhengyawei developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT zhouenchao developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT heweiming developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT sunwei developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease
AT zhanglu developmentandvalidationofanovelnomogramtopredictoverallsurvivalofpatientswithmoderatetoseverechronickidneydisease